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OBJECTIVE — Albuminuria in type 2 diabetic patients is a risk factor for cardiovascular
disease. We investigated the correlation between albuminuria and spontaneous microaggrega-
tion of platelets (SMAP) formed under shear stress.
RESEARCH DESIGN AND METHODS — The study subjects were 401 type 2 diabetic
individuals (252 with normoalbuminuria and 149 with albuminuria) who were examined for
SMAP under conditions of shear stress only (no agonist stimulation) and the reversibility of
platelet microaggregation after stimulation with 1 mol/l ADP, measured by a laser light-
cattering method. Active glycoprotein IIb/IIIa (GPIIb/IIIa) and P-selectin expression levels on
platelets as an index of platelet activation were measured by whole-blood ﬂow cytometry.
RESULTS — SMAP formation was noted in 53% of diabetic patients. All patients with SMAP
showed an irreversible pattern of platelet microaggregates by a low dose of ADP. SMAP was
observed in 75% of diabetic subjects with albuminuria and in 39% of those with normoalbu-
minuria. Multivariate logistic regression analysis identiﬁed urinary albumin excretion rate and
brachial-ankle pulse-wave velocity as independent factors associated with SMAP. The degree of
SMAP correlated with active GPIIb/IIIa (0.59, P  0.001) and P-selectin (0.55, P 
0.001) expression levels. These early-activated platelet proﬁles were signiﬁcantly inhibited in
albuminuric patients with aspirin intake, although the effect was incomplete.
CONCLUSIONS — Our study demonstrated an independent association between albumin-
uria and early changes in activated platelet proﬁles of type 2 diabetic patients. Further follow-up
and intervention studies are needed to establish whether the inhibition of SMAP affects the
course of cardiovascular disease in type 2 diabetic patients.
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T
here is growing evidence that in-
creased urinary albumin excretion
rate(AER)intype2diabeticpatients
is both a predictor of progression to
chronic renal failure and an independent
risk factor for cardiovascular disease (1).
The U.K. Prospective Diabetes Study
(UKPDS) group demonstrated that type 2
diabetic patients with microalbuminuria
or overt proteinuria have a two- to three-
fold greater risk of cardiovascular death,
compared with those patients with nor-
moalbuminuria (2). Furthermore, our
group and others recently reported that a
reduction of AER in type 2 diabetic pa-
tients was associated with a decreased oc-
currence of cardiovascular complications
(3,4). Thus, albuminuria is considered an
important therapeutic target for cardio-
vascular protection. However, the patho-
physiological factors underlying this
cardiorenal interaction remain unknown.
Identifying such factors and developing
tools to identify patients at higher risk of
both conditions might allow the design of
new therapeutic strategies to improve
outcomes in type 2 diabetic patients.
Plateletactivationandaggregationare
fundamental processes in the develop-
ment of atherosclerosis and thrombosis,
both of which contribute to cardiovascu-
lar risk (5,6). Platelets aggregate when ac-
tivated, to form microaggregates of only a
few cells as the initial response to various
stimuli but large, tighter platelet aggre-
gates appear with prolonged stimulation
(7). In diabetic patients, platelets tend to
hyperaggregate (8), although previous
plateletaggregationmeasurementsbyop-
tical density (9) or impedance methods
(10) generally reﬂected the formation of
largeplateletaggregatesinresponsetoex-
ogenous stimulation with various ago-
nists.Theseconventionalmethodsdonot
measure platelet microaggregate forma-
tion, which occurs at the initial process of
platelet activation. Recently, a particle-
counting method based on laser light
scatteringwasdevelopedtoeffectivelyde-
tect platelet microaggregate formation
(11). This new method also measures
spontaneous microaggregation of plate-
lets (SMAP), which occurs with a stirring
force only and has no requirement for ex-
ogenous agonist stimulation. Using this
newmethod,Matsunoetal.(12)reported
SMAP as the predominant platelet aggre-
gation event in type 2 diabetic patients.
However, this study did not address
the association between SMAP and
albuminuria.
We therefore investigated the associ-
ation between changes in early-activated
platelet proﬁles and increased albumin-
uria in type 2 diabetic patients. The inci-
dence of SMAP was investigated in
relation to albuminuria status. To further
evaluate the active state of SMAP, we si-
multaneously measured the cell surface
expression levels of two markers of
platelet activation: active ﬁbrinogen recep-
tor glycoprotein IIb/IIIa (GPIIb/IIIa), an
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P-selectin (CD62p), a transmembrane
protein present in the - (or dense)
granules.
RESEARCH DESIGN AND
METHODS— The diabetic subjects
were recruited from type 2 diabetic pa-
tientswhoregularlyvisitedtheoutpatient
clinic of the Department of Medicine,
Shiga University of Medical Science, in
2006–2007.Patientswereclinicallydiag-
nosed with type 2 diabetes in accordance
with the criteria of the World Health Or-
ganization. Patients were excluded based
on the following criteria: complicating
cancer, liver disease, infectious disease,
collagen disease, nondiabetic kidney dis-
ease conﬁrmed by renal biopsy, intake of
nonsteroidal anti-inﬂammatory drugs
within the previous 2 weeks, and intake
of antiplatelet drugs with the exception of
aspirin.Eligiblepatientswereinformedof
the study protocol in oral and written
forms. A total of 401 patients were ﬁnally
enrolled in this study. Thirty healthy vol-
unteers were also enrolled as the healthy
controlgrouptoconﬁrmtheresultsofour
previous study (17 male and 13 female,
aged 60  7 years [mean  SD], BMI
23.12.9kg/m
2,systolicbloodpressure
131  9 mmHg, total cholesterol 199 
20 mg/dl, triglycerides 109.8  26.4
mg/dl, and taking no medication). Each
individual provided a blood sample for
biochemical analysis and detection of
platelet microaggregation under fasting
conditions and underwent standard
physical examinations; brachial-ankle
pulse-wave velocity (baPWV) was also
measured. AER was determined by an
immunoturbidimetry assay (Hitachi
7070E; Hitachi High-Technologies, Tokyo,
Japan) in a single 24-h urine sample col-
lected on the same day as the blood sample
was collected. AER 20 g/min was con-
sidered normoalbuminuria, and AER 20
was classiﬁed as albuminuria. The group
with albuminuria comprised 120 patients
with microalbuminuria (20 g/min 
AER  200 g/min) and 29 patients with
overt proteinuria (200 g/min  AER).
aPWV was measured by an automatic de-
vice (BP-203RPE; Colin, Komaki, Japan).
The estimated glomerular ﬁltration rate
(eGFR) was calculated using the simpliﬁed
prediction equation proposed by the Japa-
nese Society of Nephrology: eGFR (millili-
ters per minute per 1.73 m
2)194 (age
[years])
0.287  (serum creatinine [milli-
grams per deciliter])
1.094  0.739 (if
female).
The study protocol and informed
consent procedure were approved by the
Ethics Committee of Shiga University of
Medical Science. All participants pro-
vided written informed consent.
Detection of platelet
microaggregation
Platelet-rich plasma was obtained from
blood collected into sodium citrate (14
mol/l) by immediate centrifugation at
155gfor12minatroomtemperature.The
platelet-rich plasma was removed and
centrifuged at 1,750g for 10 min at room
temperature in the presence of prosta-
glandin I2 (20 mol/l). The resultant
platelets were washed with HEPES-
Tyrode buffer and resuspended to 4 
10
8 cells/ml. In this platelet suspension,
plateletsdidnotformthemicroaggregates
without stirring force or any exogenous
agonists. Platelet microaggregation was
determined by measuring the light-
scattering intensity (13) on a PA-200 ag-
gregometer (Kowa, Tokyo, Japan). SMAP
was observed under low shear stress con-
ditions at a stirring speed of 1,000 rpm
(26dyn/cm
2)withoutstimulationwithan
exogenous agonist. This degree of low
shear stress is considered to be the same
degree of shear stress occurring in the
arterial stream, suggesting that this sys-
temprovidesaconditionthatmimicked
the state of platelets in the artery. The
reversibility of platelet microaggrega-
tion in response to a low dose of ADP (1
mol/l) was also investigated. The data
were recorded as a two-dimensional
graph showing the change in total light
intensity over time, expressed as a cu-
mulative summation at 10-s intervals of
scattered light intensity (Ii) and the
number of particles corresponding to
that intensity (Ni) in terms of particle
size (intensity) (	IiNi) (volts  counts
per second). Particles with an intensity
of 25–400 mV represented small aggre-
gates (9–25 m). The degree of SMAP
was described by measurement of the
area under the curve (AUC) of each de-
tection line for 5 min. AUC data were
expressed as 10
5 particles. Each mea-
surement was performed twice. All in-
dividuals showed identical results as to
whether SMAP was formed. The mean
values of two AUC measurements as the
degree of SMAP in each individual were
used for the analysis to minimize the
variability.
Quantiﬁcation of GPIIb/IIIa and
P-selectin expression levels
The platelet surface expression levels of
GPIIb/IIIaandP-selectinwereassessedby
whole-blood ﬂow cytometry using a ﬂuo-
rescein isothiocyanate-conjugated PAC-1
antibodyandaphycoerythrin-conjugated
CD62p antibody, as described previously
(14,15). In brief, a saturating antibody
concentrationin50lwasaddedto50l
of whole blood. Negative control samples
contained prepared IgG and IgM. The
samples were incubated for 15 min at
room temperature and then were ana-
lyzed within2hb yﬂ o wcytometry. The
platelets were identiﬁed based on particle
size and complexity using a peridimin-
chlorophyll-conjugated CD61 antibody.
Fluorescence data from 10,000 platelet
eventswerecollected.Theexpressionlev-
els were expressed as a percentage of the
positivelyidentiﬁedplatelets.Allantibod-
ies were purchased from BD Biosciences
(San Jose, CA).
Statistical analysis
Categorical variables were compared be-
tween the two groups using 

2 tests, an
unpaired Student t test was used for nor-
mally distributed variables, and the
Mann-Whitney U test was used for non-
normally distributed variables. For the
nonparametric comparison among four
groups, a Kruskal-Wallis test was ﬁrst
performed to ﬁnd a measure of the aggre-
gatedegreetowhichthegroupmeansdif-
fered and then the Mann-Whitney U test
with Bonferroni correction was used to
compare the differences between groups.
A Spearman correlation coefﬁcient was
used to analyze the association between
two variables. A multivariate logistic re-
gression model was applied to evaluate
the independence of factors that were sig-
niﬁcantly different between the groups,
using logarithmic transformed values of
nonnormally distributed variables. All
data were analyzed using the SPSS soft-
warepackage(version11;SPSS,Chicago,
IL). P 0.05 was considered statistically
signiﬁcant.
RESULTS




not in any of the 30 healthy volunteers
tested here (Fig. 1B) or in our previous
study (12). The diabetic patients with
SMAP showed an abnormal and irrevers-
Araki and Associates
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even after stimulation by a low dose of
ADP (Fig. 1C), whereas a normal revers-
ible pattern was observed in patients
without SMAP and in all healthy volun-
teers(Fig.1D).Table1providesdetailsof
the clinical characteristics of the diabetic
subgroups according to the formation of
SMAP. Waist-to-hip ratios, the frequency
of taking renin-angiotensin system inhib-
itors, urinary AER, eGFR, and baPWV
were signiﬁcantly different between dia-
betic patients with SMAP and those
without such events. Multiple logistic
regressionanalysisincludingthesefactors
identiﬁedthelevelsofAER(oddsratio3.4
[95% CI 2.2–5.3], P  0.001) and
baPWV (15.3 [1.1–227.5], P  0.05) as




Next, the frequency and degree of SMAP
were analyzed according to albuminuria
status (20 g/min). The frequency of
the formation of SMAP in diabetic pa-
tients with albuminuria was signiﬁcantly
higherthaninthosewithnormoalbumin-
uria (75% of 149 patients with albumin-
uria vs. 39% of 252 patients with
normoalbuminuria, P  0.001). Simi-
larly, the degree of SMAP evaluated by
AUC was signiﬁcantly higher in those
with albuminuria than in those with nor-
moalbuminuria(0.52[interquartilerange
0.01–1.46] vs. 0.00 [0.00–0.16], P 
0.001). In addition, the degree of SMAP
wassigniﬁcantlycorrelatedwiththelevels
of urinary AER as continuous variables
(Spearman0.43,P0.001).Regard-
lessofthestatusofalbuminuria,theplate-
let microaggregates in all patients with
SMAP showed the irreversible pattern af-
ter stimulation by a low dose of ADP, and
those in the patients without SMAP were
reversible.
Effect of aspirin medication on
platelet microaggregation
We evaluated the effect of aspirin medi-
cation on the frequency and degree of
SMAP. Of the diabetic patients, 163
(41%) were prescribed 100 mg/day aspi-
rin.Patientswithalbuminuriaandaspirin
intakehadasigniﬁcantlylowerfrequency
of SMAP than those without it (50 of 76
patients taking aspirin vs. 62 of 73 pa-
tients not given aspirin), whereas the
SMAP rates were similar in the two sub-
groups in patients with normoalbumin-
uria (37 of 87 patients taking aspirin vs.
62 of 165 patients without aspirin in-
take). The degree of SMAP among the
patients with albuminuria was similarly
signiﬁcantly lower with than without
aspirin (0.33 [0.00–1.27] vs. 0.88
[0.17–1.76]), whereas patients with nor-
Figure 1—Typical patterns of SMAP and reversibility of platelet microaggregation by low-dose
ADP,measuredbyalaserlight-scatteringsystem.Thespontaneousformationofmicroaggregated
platelets under low shear stress alone without any exogenous agonists was observed in 52.6% of
diabeticpatients(A),whereasitwasnotobservedin47.4%ofdiabeticpatientsandinanyhealthy
volunteers (B). Diabetic patients with SMAP showed irreversible platelet microaggregation in
response to ADP (1 mol/l) (C), whereas the others showed the typical reversible pattern of
platelet microaggregation within 5 min (D).






Sex (male/female) 110/80 119/92
Age (years) 64  11 65  9
Duration of diabetes (years) 17  11 16  9
BMI (kg/m
2) 24.6  4.3 24.7  3.8
Waist-to-hip ratio 0.93  0.07 0.95  0.08*
A1C (%) 7.2  0.8 7.2  1.0
Diabetes treatment (%) (diet/oral agents/insulin) 11/55/34 7/49/44
Systolic blood pressure (mmHg) 133  17 134  14
Diastolic blood pressure (mmHg) 73  10 72  10
Hypertension (%) 66 74
Taking renin-angiotensin system inhibitors (%) 41 59*
Total cholesterol (mg/dl) 194  31 197  29
Triglycerides (mg/dl) 86 (61–116) 92 (62–134)
HDL cholesterol (mg/dl) 54 (46–65) 52 (45–62)
Taking statins (%) 52 48
Urinary albumin excretion rate (g/min) 9 (6–16) 23 (8–87)†
eGFR (ml/min per 1.73 m
2) 74  23 70  20*
baPWV (cm/s) 1,606 (1,416–1,800) 1,726 (1,521–1,987)†
Taking aspirin (%) 40 41
Current smoking (%) 22 21
Data are means  SD for normally distributed continuous variables or medians (25th–75th interquartiles)
for skewed continuous variables. *P  0.05, †P  0.01 vs. diabetic subjects without SMAP.
Activated platelet proﬁle and albuminuria
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ence according to aspirin intake (0.00
[0.00–0.14] vs. 0.00 [0.00–0.21]) (Fig.
2). In addition, the strong correlation be-
tween the degree of SMAP and the levels
of urinary AER as continuous variables
was investigated in the patients without
aspirin intake (0.53, P  0.001),
whereas the weak association between
them was found in those with aspirin in-
take (0.27, P  0.001).
Correlation between platelet
microaggregation and GPIIb/IIIa and
P-selectin expression
To further evaluate the active state of
SMAP, we quantitated the expression lev-
els of active GPIIb/IIIa and P-selectin on
the platelets. The expression levels of ac-
tive GPIIb/IIIa were higher in diabetic pa-
tients with SMAP than in those without
SMAP (29.9% [interquartile range 19.3–
42.2] vs. 15.5% [11.7–21.9]). Similarly,
the expression levels of P-selectin were
higherindiabeticpatientswithdetectable
SMAP than those without it (8.1% [5.1–
16.0]vs.4.4%[3.2–5.6]).Theexpression
levels of both markers correlated signiﬁ-
cantly with the degree of SMAP (Spear-
man 0.59 for active GPIIb/IIIa and
0.55 for P-selectin).
Finally, we investigated the relation-
ship between the expression levels of
these surface markers and urinary AER in
the subgroups based on aspirin intake. In
patientsnottakingaspirin,theexpression
level of each surface marker correlated
signiﬁcantlywithurinaryAER(Spearman
0.60 for active GPIIb/IIIa and 
0.57 for P-selectin) (Fig. 3A and C). Sim-
ilar correlations were also observed in pa-
tients taking aspirin, albeit with a slightly
weaker coefﬁcient of correlation (Spear-
man 0.51 for active GPIIb/IIIa and
0.34 for P-selectin, Fig. 3B and D).
CONCLUSIONS — The present study
provided new evidence that both in-
creasedAERandbaPWVareindependent
factors associated with the abnormal for-
mation of SMAP in type 2 diabetic pa-
tients. Furthermore, the patients with
SMAP showed an irreversible pattern of
platelet microaggregation by ADP, and
the degree of SMAP correlated with the
enhanced expression of active GP IIb/IIIa
and P-selectin, indicating that SMAP is
pathophysiologically active. These early-
activated platelet proﬁles were signiﬁ-
Figure2—Box-and-whiskerplotsofSMAPas-
sessed by AUC in diabetic patients with nor-
moalbuminuria and albuminuria, treated with
or without aspirin. In these plots, lines within
the boxes represent median values; the upper
and lower lines of the boxes represent the 25th
and 75th percentiles, respectively; and the up-
per and lower bars outside the boxes represent
the 90th and 10th percentiles, respectively.
Kruskal-Wallistest:P0.001,*P0.001vs.
normoalbuminuric patients treated with and
withoutaspirin,†P0.01vs.albuminuricpa-
tients without aspirin (Mann-Whitney U test).
Figure 3—Correlation between urinary albumin excretion rate and expression of platelet surface markers, active GPIIb/IIIa, and P-selectin. The
patientsweredividedintotwosubgroupsbasedonaspirinintake:foractiveGPIIb/IIIa,thosenottakingaspirin(A)(0.60;P0.001)andthose
taking aspirin (B)(   0.51; P  0.001), and for P-selectin, those not taking aspirin (C)(   0.57; P  0.001) and those taking aspirin (D)(  
0.34; P  0.001). Log-transformed values were plotted on each ﬁgure.
Araki and Associates
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with aspirin intake, although the effect
was incomplete.
Assessment of inappropriate platelet
activation is one way to risk-stratify pa-
tients who are at high risk of athero-
sclerosis and atherothrombosis. The
microaggregates produced in the early
phase of platelet activation are now con-
sideredtopotentiallyaggravatethrombus
formation (7). Under normal conditions,
these platelet microaggregates dissolve
within a few minutes, as shown in this
study(Fig.1D).Inthepresentstudy,53%
of type 2 diabetic patients showed SMAP
and abnormal irreversibility of the micro-
aggregation after low-dose ADP. This
high proportion of diabetic patients with
abnormal platelet hyperaggregability is in
agreement with the result from a cohort
studied previously (12). The SMAP for-
mation was observed under a low-shear
stress that mimicked the state of the arte-
rial bloodstream without the stimulation
of exogenous agonists. In addition, the
degree of SMAP was associated with en-
hanced expression of active GPIIb/IIIa
and P-selectin. Thus, the formation of
SMAPisconsideredtoshowtheabnormal
activated state of platelets in diabetic pa-
tients,whichisenhancedaccordingtothe
increase of albuminuria.
In the present study, SMAP occur-
rence was associated with both albumin-
uria and baPWV. In agreement with these
results, other investigators reported that
high levels of platelet microaggregation
were associated with adverse outcomes in
patients with cardiovascular disease (16)
and the ankle-brachial index in patients
with peripheral arterial disease (17). In
addition, diabetic patients with SMAP
showed overexpression of platelet surface
markers,activeGPIIb/IIIa,andP-selectin.
Such upregulation of these molecules has
also been associated with the develop-
ment of atherogenesis (18). Taken to-
gether,theearlyplateletactivationintype
2 diabetic patients may be a risk factor for
cardiovascular disease.
A recent guideline of the American
Diabetes Association recommended pro-
phylactic use of antithrombotic agents,
with low-dose aspirin, for diabetic sub-
jects, especially those with albuminuria
(19). However, Di Minno and Violi (20)
indicated that aspirin alone is insufﬁcient
topreventthrombosisindiabeticpatients
with angiopathy. In the present study,
SMAP formation was inhibited in albu-
minuric patients taking aspirin compared
with those not taking it. However, SMAP
formation was still associated with albu-
minuria, even in patients taking aspirin,
suggesting that the inhibitory effect of
aspirin may be insufﬁcient in diabetic
patients with albuminuria. Further
follow-upandinterventionstudiesarere-
quired to investigate whether the incom-
plete inhibition of early-activated platelet
proﬁles is a cardiovascular risk.
Several plausible mechanisms under-
lying the cardiorenal interaction have
been proposed. Deckert et al. (21) pro-
posed in the Steno hypothesis that excess
leakage of albumin into urine reﬂects
widespread vascular (endothelial) dam-
age. This endothelial dysfunction is con-
sidered a common feature of cardiorenal
interactions (22); it leads to platelet acti-
vation, adhesion, and subsequent platelet
aggregate formation. Platelets are also a
rich source of chemokines and cytokines,
released within seconds of platelet activa-
tion(23).Thus,theformationofSMAPin
diabetic patients with albuminuria might
either cause or reﬂect systemic vascular
endothelial dysfunction. An alternative
explanation is that any pathophysiologi-
cal alteration in a diabetic kidney could
directly affect platelet activation. Glomer-
ular hypertension, which induces me-
chanical shear stress (24), and excess
renalproductionoftypeIVcollageninthe
kidney(25),apowerfulactivatorofplate-
lets, might induce activation of platelets
that circulate into the kidney.
The present study had some limita-
tions. It was not possible to ascertain
whether the early-activated platelet pro-
ﬁle was a cause or consequence of the
increased urinary albumin excretion be-
causeofthe natureofthecross-sectional
study. The present study also could not
address whether the incidence of future
cardiovascular disease is higher in pa-
tients with SMAP and whether the in-
hibitory effect of aspirin on the degree
of SMAP would be sufﬁcient to prevent
the development of cardiovascular
disease.
In summary, the majority of type 2
diabetic patients with albuminuria
showed an altered proﬁle of early platelet
activation including SMAP events. Given
the growing concern over cardiovascular
consequences in type 2 diabetic patients,
further follow-up and intervention stud-
ies are needed to establish whether the
inhibition of SMAP is a therapeutic target
to prevent cardiovascular complications
in type 2 diabetic patients.
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